Gabriel L. Hendricks, Ph.D.
Gabriel works on patents within the Biotechnology sector.

- Offices
- Phone
- vCard
Gabriel’s work includes patent prosecution in the biotechnology sector, including cancer biology and therapeutics, immunology, small molecule therapeutics, and research tools.
Gabriel has managed all aspects of patent portfolios across various technologies, including US and foreign patent applications for mechanical, chemical, software, and biology inventions. Prior to joining ArentFox Schiff, Gabriel was a patent agent at a mid-sized law firm in Boston.
Gabriel received his PhD in Biomedical Research from the University of Massachusetts Medical School. His research focused on the immunology of RNA and DNA viruses and antiviral therapeutics against these viruses. At UMass, he worked on novel decoy liposomes that could be produced on demand with different viral receptors, thereby acting as a molecular sink and infection dead-end. Gabriel has authored and presented numerous scientific publications in the fields of viral immunology, antivirals, antimicrobials, antifungals, and neuroscience.
Publications, Presentations & Recognitions
Publications
- Kim W, Zhu W, Hendricks GL, Van Tyne D, Steele AD, Keohane CE, Fricke N, Conery AL, Shen S, Pan W, Lee K, Rajamuthiah R, Fuchs BB, Vlahovska PM, Wuest WM, Gilmore MS, Gao H, Ausubel FM, Mylonakis E. A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature. 2018 Apr 5;556(7699):103-107. doi: 10.1038/nature26157. Epub 2018 Mar 28. PMID: 29590091; PMCID: PMC6462414.
- Kim W, Zou G, Hari TPA, Wilt IK, Zhu W, Galle N, Faizi HA, Hendricks GL, Tori K, Pan W, Huang X, Steele AD, Csatary EE, Dekarske MM, Rosen JL, Ribeiro NQ, Lee K, Port J, Fuchs BB, Vlahovska PM, Wuest WM, Gao H, Ausubel FM, Mylonakis E. A selective membrane-targeting repurposed antibiotic with activity against persistent methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A. 2019 Aug 13;116{33):16529-16534. doi: 10.1073/pnas.1904700116. Epub 2019 Jul 29. PMID: 31358625; PMCID: PMC6697817.
- Kim W, Hendricks GL, Tori K, Fuchs BB, Mylonakis E. Strategies against methicillin-resistant Staphylococcus aureus persisters. Future Med Chem. 2018 Apr 1;10(7):779-794. doi:10.4155/fmc-2017-0199. Epub 2018 Mar 23. PMID: 29569952; PMCID: PMC6077763. Accordion Toggle
Presentations
- “Combining Research Science & Intellectual Property as a Patent Agent,” Speaker, The University of Massachusetts Medical School, Jan. 2019
-
IndustriesPractices
-
Education
University of Massachusetts Medical School, PhDOberlin College, BA